BLIS Technologies Ltd
BLT
Company Profile
Business description
BLIS Technologies Ltd is engaged in developing oral probiotics. The company markets strains of probiotic bacteria BLIS K12, BLIS Q24, and BLIS M18 which occur naturally in the oral cavity. Its product portfolio consists of probiotic serum, Teeth and gums lozenge, fresh breath lozenge, and immune lozenge. Geographically, the company derives a majority of its revenue from EMEA (Europe, the Middle East, and Africa).
Contact
442 Moray Place
Ground Floor
DunedinOTA9016
NZLT: +64 34740988
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 March 2025
Employees
34
Stocks News & Analysis
stocks
We think lithium prices may have hit bottom - our cheapest ASX picks
Our recent price forecasts may provide some relief to investors after an agonising few years for those invested in the lithium game.
stocks
Ask the analyst: Did the rise of passive doom Platinum and Perpetual?
A reader asked what is behind the poor performance of Platinum and Perpetual shares in recent years. Shaun Ler stepped in to answer.
stocks
5 undervalued US shares that crushed earnings
These stocks are still cheap despite impressive earnings.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,592.30 | 36.90 | -0.43% |
| CAC 40 | 7,229.64 | 48.59 | -0.67% |
| DAX 40 | 19,060.31 | 128.88 | -0.67% |
| Dow JONES (US) | 43,268.94 | 120.66 | -0.28% |
| FTSE 100 | 8,099.02 | 10.30 | -0.13% |
| HKSE | 19,639.78 | 23.89 | -0.12% |
| NASDAQ | 18,987.47 | 195.66 | 1.04% |
| Nikkei 225 | 38,242.35 | 172.08 | -0.45% |
| NZX 50 Index | 12,724.25 | 92.07 | -0.72% |
| S&P 500 | 5,916.98 | 23.36 | 0.40% |
| S&P/ASX 200 | 8,339.40 | 34.60 | -0.41% |
| SSE Composite Index | 3,354.95 | 8.94 | 0.27% |